Redeye embraces AroCell’s Q1’22 report, demonstrating good cost control and higher sales than expected (albeit still in small figures). We slightly up our Base Case following the report - our fair value range suggests a hefty upside from today’s share price levels, but we emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/